Stock News

Nektar Posts Better-Than-Feared Quarterly Loss, Misses On Revenues
FOCUS-AstraZeneca, Sputnik vaccines face hurdles if COVID shots become annual affair
Merck Inks Deal To Buy Pandion Therapeutics For $1.85B; Shares Skyrocket
Cancer drug is first to begin fast-track UK approval process
UPDATE 1-Merck says FDA requires more data on its COVID-19 drug
SHAREHOLDER ALERT: WeissLaw LLP Investigates Pandion Therapeutics, Inc.
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Pandion Therapeutics, Inc. Buyout
PANDION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PAND and Encourages Investors to Contact the Firm
Merck to Buy Autoimmune Drug Developer for $1.85 Billion
Pandion Therapeutics Doubles on Planned $1.85B Purchase by Merck
There's More to Merck's New 'Bean Counter' CEO Than First Appears
Top 15 Pharmaceutical Companies With Highest R&D Spending
Veru Files US Application For TADFIN Combo For Prostate Enlargement

As seen on...